<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>ABT score &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/abt-score/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 24 Oct 2026 09:07:07 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>ABT score &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Simple Blood-Based ABT Score Predicts Survival in Liver Cancer Patients on Triple Therapy</title>
		<link>https://bioengineer.org/simple-blood-based-abt-score-predicts-survival-in-liver-cancer-patients-on-triple-therapy/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 24 Oct 2026 09:07:07 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[ABT score]]></category>
		<category><![CDATA[bevacizumab]]></category>
		<category><![CDATA[biomarker]]></category>
		<category><![CDATA[Hepatocellular Carcinoma]]></category>
		<category><![CDATA[immune checkpoint inhibitor]]></category>
		<category><![CDATA[liver cancer]]></category>
		<category><![CDATA[overall survival]]></category>
		<category><![CDATA[prognosis prediction]]></category>
		<category><![CDATA[risk stratification]]></category>
		<category><![CDATA[sintilimab]]></category>
		<category><![CDATA[TACE]]></category>
		<category><![CDATA[triple therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=451491</guid>

					<description><![CDATA[A retrospective three-center study of 156 patients shows that a new ABT score, built from the alkaline phosphatase to prealbumin ratio, BCLC stage, and total bilirubin, reliably stratifies survival risk in unresectable hepatocellular carcinoma patients treated with TACE plus bevacizumab and sintilimab.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">451491</post-id>	</item>
	</channel>
</rss>
